Veracyte Inc. logo

Veracyte Inc. (VCYT)

Market Closed
12 Jun, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
47. 33
-0.09
-0.1898%
Pre Market
$
48. 20
+0.87 +1.8382%
3.84B Market Cap
- P/E Ratio
- Div Yield
1.08M Volume
-0.74 Eps
$ 47.42
Previous Close
Add Transaction
Day Range
46.04 48.62
Year Range
22.61 50.71
Want to track VCYT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates

Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to loss of $0.04 per share a year ago.

Zacks | 1 year ago
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?

Is Veracyte Stock a Good Addition to Your Portfolio Right Now?

VCYT stays on investors radar due to the strong performance of the Afirma and Decipher franchises.

Zacks | 1 year ago
Veracyte Gains 44% in a Year: What's Driving the Stock?

Veracyte Gains 44% in a Year: What's Driving the Stock?

VCYT is gaining shares due to the strength of its Afirma and Decipher tests.

Zacks | 1 year ago
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

Veracyte's progress with key drivers and the strength in its diagnostics tests bring optimism to investors.

Zacks | 1 year ago
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Zacks | 1 year ago
Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised

Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.

Zacks | 1 year ago
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Seekingalpha | 1 year ago
Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates

Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago.

Zacks | 1 year ago
Veracyte: Revolutionizing Noninvasive Cancer Diagnostics

Veracyte: Revolutionizing Noninvasive Cancer Diagnostics

In this ROBO Global Artificial Intelligence Index spotlight, we focus on Veracyte (VCYT). The index underlies the $137 million ROBO Global Artificial Intelligence ETF (THNQ).

Etftrends | 1 year ago
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Zacks | 1 year ago
Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?

Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Here's Why Veracyte (VCYT) is a Strong Momentum Stock

Here's Why Veracyte (VCYT) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Loading...
Load More